{"classes":[{"categories":[{"measurements":[{"comment":"Median was not reached due to low number of participants with events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median was not reached due to low number of participants with events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median was not reached due to low number of participants with events.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"17"}],"units":"Participants"}],"description":"OS is the time in months from start of study treatment to date of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Brentuximab vedotin 1.4 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle, until there was evidence of disease progression or unacceptable toxicity.","id":"OG000","title":"Brentuximab Vedotin 1.4 mg/kg: Phase 1"},{"description":"Participants with r/r HL received brentuximab vedotin 1.8 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle until there was evidence of disease progression or unacceptable toxicity (Up to 16 cycles). Treatment with brentuximab vedotin beyond 16 cycles was permitted at the joint discretion of the sponsor and the investigator for those participants experiencing continued clinical benefit.","id":"OG001","title":"Brentuximab Vedotin 1.8 mg/kg: Phase 1 and 2 r/r HL Only"},{"description":"Participants with r/r systemic anaplastic large-cell lymphoma (sALCL) received brentuximab vedotin 1.8 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle until there was evidence of disease progression or unacceptable toxicity (Up to 16 cycles). Treatment with brentuximab vedotin beyond 16 cycles was permitted at the joint discretion of the sponsor and the investigator for those participants experiencing continued clinical benefit.","id":"OG002","title":"Brentuximab Vedotin 1.8 mg/kg: Phase 1 and 2 r/r sALCL Only"}],"paramType":"MEDIAN","populationDescription":"Safety population is defined as all participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"Every 6 months after EOT, until the sooner of death, study closure, or 2 years after enrolment of the last participant (Up to 72 months)","title":"Overall Survival (OS) (Phase 1 and 2)","type":"SECONDARY","unitOfMeasure":"months"}